Chronic Myeloid Leukemia, Chronic Phase Clinical Trial
Official title:
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
The purpose of this study is to determine if adding Ruxolitinib to a Tyrone Kinase Inhibitor (TKI), prior to a second attempt at stopping a TKI will lead to prolonged treatment free remission (TFR).
All participants will have a confirmed diagnosis of chronic phase chronic myeloid leukemia (CML) and must have previously attempted to discontinue TKI therapy. All participants must be restarted on a TKI at the time of relapse in order to be eligible for this trial. After completion of 12 cycles of combination therapy, eligible participants will remain in the TFR phase of the study for up to 36 months, and will have central polymerase chain reaction (PCR) testing during the first 24 months. Therefore, the total duration of the trial will be approximately 48 months (12 months on combination treatment phase + 36 months in the TFR phase). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06409936 -
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
|
Phase 2 | |
Terminated |
NCT04006847 -
Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06368414 -
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia
|
Phase 2 | |
Active, not recruiting |
NCT04126681 -
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
|
Phase 2 | |
Not yet recruiting |
NCT05543161 -
"Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker"
|
||
Recruiting |
NCT05638763 -
Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia
|
Phase 2 | |
Completed |
NCT03332511 -
Efficacy and Safety of Nilotinib in CML-CP
|
Phase 4 | |
Active, not recruiting |
NCT06233890 -
The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia
|
||
Completed |
NCT03882281 -
Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT03459534 -
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
|
Phase 3 | |
Completed |
NCT03885830 -
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
|
||
Active, not recruiting |
NCT04147533 -
Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT03942094 -
Nilotinib for First-line Newly Diagnosed CML-CP Patients
|
Phase 3 | |
Active, not recruiting |
NCT03933852 -
Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose
|
||
Recruiting |
NCT05311943 -
Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.
|
Phase 3 | |
Active, not recruiting |
NCT04160546 -
Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)
|
Phase 2 | |
Recruiting |
NCT04677439 -
Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure
|
Phase 4 | |
Active, not recruiting |
NCT03722420 -
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
|
Phase 3 | |
Not yet recruiting |
NCT06163430 -
CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia
|
Phase 1 | |
Completed |
NCT02977312 -
Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan
|
N/A |